EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. - Institut Pasteur Access content directly
Journal Articles Oncotarget Year : 2015

EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.

Abstract

EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy.
Fichier principal
Vignette du fichier
2870-46383-3-PB.pdf (5.16 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

pasteur-01573832 , version 1 (10-08-2017)

Licence

Attribution

Identifiers

Cite

Farah Khayati, Laura Pérez-Cano, Kamel Maouche, Aurélie Sadoux, Zineb Boutalbi, et al.. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.. Oncotarget, 2015, 6 (12), pp.9766-80. ⟨10.18632/oncotarget.2870⟩. ⟨pasteur-01573832⟩
252 View
291 Download

Altmetric

Share

Gmail Facebook X LinkedIn More